Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Predictors of Hematologic Responses in Patients with Non-Transfusion-Dependent β-Thalassemia Receiving Thalidomide Therapy].

Zhongguo shi yan xue ye xue za zhi - 1 Oct 2022

Yang Kun, Yin Xiao-Lin, Liu Xiao-Dong, Hua Fang, Peng Wei, Li Lan, Chen Kun, Zhang Jin, Luo Shan, Xiao Jian

Abstract excerpt

OBJECTIVE: To explore the predictors of hematologic responses of non-transfusion-dependent β-thalassemia (NTDT) to thalidomide. METHODS: 33 patients with NTDT who treated with thalidomide in the 923rd Hospital of the Joint Logistics Support Force of the People's Liberation Army from May 2016 to June 2019 were included in the study. The basic data, hematological indexes, degree of treatment response and genetic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to beta-Thalassemia
Share to Fetal Hemoglobin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to MicroRNAs

Share to Polymorphism, Single Nucleotide

Share to Repressor Proteins

Share to Thalidomide

Source

Identifiers

PMID: 36208259
DOI: 10.19746/j.cnki.issn.1009-2137.2022.05.033

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Predictors of Hematologic Responses in Patients with Non-Transfusion-Dependent β-Thalassemia Receiving Thalidomide Therapy].PMID 36208259Read ↗

The association of HBG2, BCL11A, and HBS1L-MYB polymorphisms to thalidomide response in Chinese β-thalassemia patients.Semantic proximity Read ↗

Clinical efficacy of thalidomide for various genotypes of beta thalassemiaSemantic proximity Read ↗

Clinical efficacy of thalidomide for various genotypes of beta thalassemia.Semantic proximity Read ↗

Efficacy of thalidomide treatment in children with transfusion dependent β-thalassemia: a retrospective clinical studySemantic proximity Read ↗

A Pragmatic Scoring Tool to Predict Hydroxyurea Response Among β-Thalassemia Major Patients in Pakistan.Semantic proximity Read ↗

The XmnI and BCL11A single nucleotide polymorphisms may help predict hydroxyurea response in Iranian β-thalassemia patients.Semantic proximity Read ↗

A genetic score for the prediction of beta-thalassemia severity.Semantic proximity Read ↗

Response to hydroxyurea in beta thalassemia major and intermedia: experience in western India.Semantic proximity Read ↗

Association of CYP2C19 gene single nucleotide polymorphisms (rs12248560 and rs4244285) with response to thalidomide in transfusion dependent β-thalassemia patients- a 12-months follow-up study.Semantic proximity Read ↗

Decreased transfusion needs associated with hydroxyurea therapy in Algerian patients with thalassemia major or intermedia.Semantic proximity Read ↗

Drug repurposing: Hydroxyurea therapy improves the transfusion-free interval in HbE/beta-thalassemia–major patients with Xmn1 polymorphismSemantic proximity Read ↗

Genotype-phenotype relationship of patients with β-thalassemia taking hydroxyurea: a 13-year experience in Iran.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.